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Abstract
Background: Microvascular invasion (MVI) is recognized as a prognostic factor associated with poor outcome in
hepatocellular carcinoma (HCC) patients after curative resection. It remains unclear, however, whether MVI can
provide prognostic information for patients at a specific tumor stage.
Methods: Consecutive HCC patients who underwent curative resection in years of 2007 and 2008 (discovery
cohort) were enrolled in this retrospective study. Patients were stratified by the Barcelona Clinic Liver Cancer (BCLC)
staging system. The prognostic significance of MVI for overall survival (OS) and recurrence-free survival (RFS) was
studied in each subgroup. The clinical significance of MVI was validated in another cohort of patients underwent
curative surgery in the year of 2006 (validation cohort).
Results: Of the 1540 patients in the discovery cohort, 389 (25.3%) patients had detectable MVI. Occurrence rates of
MVI in the BCLC stage 0, A, and B subgroups were 12.4, 26.2, and 34.4%, respectively. In univariate analysis, MVI was
associated with poor OS and RFS (P < 0.001 for both) in HCC patients at stage A, with poor OS in patients at stage
0 (P = 0.028), and with poor RFS at stage B (P = 0.039). In multivariate analysis, MVI was an independent risk factor
for OS (HR = 1.431, 95% CI, 1.163–1.761, P < 0.001) and RFS (HR = 1.400, 95% CI, 1.150–1.705, P = 0.001) in patients at
stage A; and an independent risk factor for RFS (P = 0.043) in patients at stage B. A similar clinical significance of
MVI was found in the validation cohort.
Conclusions: MVI has limited prognostic value for HCC patients at BCLC stages 0 and B. For those at stage A, MVI
was associated with patient survival and may help to select patients with high risk of disease recurrence.
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Background
Liver cancer (mostly hepatocellular carcinoma; HCC) is
the second leading cause of cancer-related mortality
worldwide [1]. Only approximately 20% of patients with
early stage HCC are amenable to curative treatments
such as liver resection, liver transplantation, and loco-
regional therapies. Although surgical treatments have
significantly improved the overall survival, long-term
survival is still poor due to high rates of tumor recur-
rence and metastasis after surgery [2].
Microvascular invasion (MVI) is defined as the pres-
ence of tumor cells in portal veins, in large capsule ves-
sels, or in a vascular space lined by endothelial cells [3].
MVI is an early means of cancer cell spread via the vas-
culature [4]. MVI is only visible on microscopy, and it is
difficult to be detected before surgical resection [5]. MVI
was found to be one of the most important risk factors
for intrahepatic recurrence in HCC patients who under-
went curative surgery; thus, it may serve as a surrogate
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marker reflecting tumor biological characteristics [6, 7],
and was recognized as an independent predictor of early
recurrence and poor overall survival (OS) following liver
resection and liver transplantation [8–10]. However,
some authors recently proposed that MVI was not a
prognostic factor for all HCC patients. In those with
small HCC (≤2 cm), although MVI exhibited excellent
prognostic significance [11], it had limited clinical value
for treatment and prognosis as compared with the Milan
criteria [12]. Thus, whether MVI is associated with pa-
tient prognosis only at a specific stage still requires fur-
ther study.
To date, several HCC staging systems have been pro-
posed to stratify patients into subgroups for better treat-
ment decisions and prognostic prediction [2]. Among
these, the Barcelona Clinic Liver Cancer (BCLC) classifi-
cation is recommended by the American Association for
the Study of Liver Diseases (AASLD) and the European
Association for the Study of the Liver (EASL) [13, 14].
According to the EASL/AASLD guidelines, hepatic re-
section is only indicated for BCLC stage 0 or A patients
but not for stages B or C. Recently, some authors pro-
posed that the intermediate stage of HCC (BCLC stage
B) includes a wide range of patient populations in term
of tumor burden and patients’ survival [15]. Several
studies have shown that a subset of patients in BCLC
stage B will benefit from liver resection over transcathe-
ter arterial chemoembolization (TACE), which is the
standard of care for patients at stage B according to
EASL/AASLD recommendation [16–18]. Therefore,
liver resection is still an important option for patients at
stage B in many centers [19–22], as well as in the au-
thors’ institute.
For patients who undergo curative liver resection,
pathological findings should be integrated for more pre-
cise staging and estimation of risk of tumor recurrence
as compared with preoperative stage. For example, MVI
could provide additional information for the prognosis
prediction and help to select patients with high risk of
tumor recurrence for adjuvant therapies. In the current
study, we aimed to evaluate whether MVI is an inde-
pendent risk factor for HCC patients stratified by the
BCLC staging system in a cohort of consecutive patents
in the authors’ institute, and tried to find the basis for




Treatment-naïve patients with histologically diagnosed
HCC who underwent curative resection in the authors’
institute between Jan 1, 2007 to Dec 31, 2008 (discovery
cohort) were included in this study. Patients with at least
one follow-up after surgery were eligible for the present
study. Those with preoperative radiologically or intraop-
eratively diagnosed macrovascular invasion (defined as
tumor tissue found in the portal vein, bile duct, or hep-
atic vein) were excluded from this study. In all cases,
preoperative liver function was classified as Child-Pugh
class A. Tumor stage was determined according to the
BCLC staging system [23]. Tumor cell differentiation
was evaluated according to the Edmondson-Steiner clas-
sification. MVI status was determined according to
histological pathology. The diagnosis of MVI, when
tumor cells were detected in microvessels upon micro-
scopic observation, was made based on our established
criteria described elsewhere [3]. The data of MVI status
were retrospectively retrieved from pathological reports.
Patients who underwent curative liver resection in the
year of 2006 (validation cohort) were used for the valid-
ation of the clinical significance of MVI. This study was
approved by the Zhongshan Hospital Fudan University
Research Ethics Committee. Informed consent obtained
from the patients were written.
Follow-up and postoperative treatments
All patients were observed until March 2016, with a me-
dian observation time of 42.5 months. Follow-up proce-
dures were described in our previous study [24].
Diagnosis of tumor recurrence was based on at least two
imaging methods. Treatment modalities after recurrence
were administered according to a uniform guideline as
described elsewhere [24]. OS was defined as the interval
between the date of surgery and death. Recurrence-free
survival (RFS) was defined as the interval between the
date of surgery and the date of the diagnosis of tumor
recurrence or the date of disease-specific death.
Statistical analysis
Statistical analyses were performed with PASW Statistics
18.0 for Windows (IBM Inc.). In the comparison among
different subgroups, quantitative variables were com-
pared using Student’s t-test and qualitative variables
using the chi-square test or Fisher’s exact test. Kaplan-
Meier analysis was used to determine the survival rates.
Log-rank test was used to compare patient survival be-
tween subgroups, and the Cox regression model was
used to perform multivariate survival analysis. All statis-




A total of 2170 patients were included in the discovery
cohort (n = 1540) and the validation cohort (n = 630)
(Table 1). Of the patients in the discovery cohort, 84.7%
were male and 81.5% had a history of hepatitis B virus
infection, as defined by positive serum hepatitis B
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surface antigen. The mean tumor size was 5.5 ± 3.5 cm,
and 87.1% had a solitary tumor. Because patients with
extrahepatic metastasis or macrovascular invasion were
excluded in this study, all patients were BCLC stage 0,
or A, or B. Of these patients, 22.5% (346/1540) received
adjuvant TACE when tumor recurrence was not diag-
nosed. During a median follow-up of 42.5 months, the
median RFS was 50.8 months (95% confidence interval
[CI], 45.0–56.7 months) and the median OS was not
reached.
Correlations between MVI and clinical characteristics
The overall incidence of MVI was 25.3%. Compared to
those without MVI, patients with MVI had lower serum
albumin (P = 0.010), and larger tumor size (P < 0.001)
(Table 2). Patients with elevated serum α-fetoprotein
(AFP > 200 ng/dL; 49.1 vs. 34.9%, P < 0.001), large tumor
size (>5 cm, 50.1% vs. ≤5 cm, 32.1%, P < 0.001), tumors
without encapsulation (57.1 vs. 44.6%, P < 0.001), poor
differentiation of tumor cells (40.1 vs. 23.5%, P < 0.001),
or advanced BCLC tumor stage (Ptrend < 0.001) had a
higher incidence of MVI (Table 2).
Prognostic factors
As shown in Table 3, in univariate analysis, elevated
AFP, γ-GT, low serum albumin, large tumor size, mul-
tiple tumors, poor tumor cell differentiation, incomplete
tumor encapsulation, advanced BCLC stage, and MVI





Age, median (range), year 53.0 (10–86) 53.0 (12–92)
Gender, male/female 1305 (84.7%)/235 (15.3%) 530 (84.1%)/100 (15.9%)
α-Fetoprotein (>200/≤200 ng/dL) 593 (38.5%)/947 (61.5%) 259 (41.1%)/371 (58.9%)
Liver cirrhosis, yes/no/unknown 1268 (82.3%)/251 (16.3%)/21 (1.4%) 512 (81.3%)/102 (16.2%)/16 (2.5%)
Hepatitis B history, yes/no/unknown 1255 (81.5%)/254 (16.5%)/31 (2.0%) 527 (83.7%)/94 (14.9%)/9 (1.4%)
Tumor size, mean ± SD, cm 5.3 ± 3.5 5.5 ± 3.7
Tumor number, multiple/solitary 199 (12.9%)/1341 (87.1%) 78 (12.4%)/552 (87.6%)
Types of resection, anatomic/non-anatomic 1222 (79.4%)/318 (20.6%) 475 (75.4%)/155 (24.6%)
Encapsulation, complete/none/unknown 733 (47.6%)/803 (52.1%)/4 (0.3%) 294 (46.7%)/335 (53.2%)/1 (0.2%)
Tumor differentiation, I–II/III–IV/unknown 1098 (71.3%)/421 (27.3%)/21 (1.4%) 441 (70.0%)/171 (27.1%)/18 (2.9%)
Microvascular invasion, yes/no 389 (25.3%)/1151 (74.7%) 205 (32.5%)/425 (67.5%)
BCLC stage, 0/A/B 194 (12.6%)/1192 (77.4%)/154 (10.0%) 87 (13.8%)/484 (76.8%)/59 (9.4%)
Table 2 Relationships between microvessel invasion and clinicopathological features in the discovery cohort
Variables Microvessel invasion
Yes (n = 389) No (n = 1151) P
Age, year 52.1 ± 11.6 53.3 ± 11.7 0.082
Gender, male/female 332 (85.3%)/57 (14.7%) 973 (84.5%)/178 (15.5%) 0.700
Hepatitis B history, yes/no 317 (83.6%)/62 (16.4%) 938 (83.0%)/192 (17.0%) 0.776
ALT, U/L 54.4 ± 84.7 50.7 ± 64.6 0.370
γ-GT, U/L 94.3 ± 84.9 86.9 ± 92.7 0.168
Albumin, g/L 40.9 ± 4.9 41.6 ± 4.6 0.010
Liver cirrhosis, yes/no 312 (81.0%)/73 (19.0%) 956 (84.3%)/178 (15.7%) 0.153
α-Fetoprotein (>200/≤200 ng/dL) 191 (49.1%)/198 (50.9%) 402 (34.9%)/749 (65.1%) <0.001
Tumor size, cm 6.5 ± 3.8 4.9 ± 3.3 <0.001
Tumor size (>5 cm/≤5 cm) 195 (50.1%)/194 (49.9%) 370 (32.1%)/781 (67.9%) <0.001
Tumor number, solitary/multiple 332 (85.3%)/57 (14.7%) 1009 (87.7%)/142 (12.3%) 0.239
Tumor encapsulation, complete/no 166 (42.9%)/221 (57.1%) 637 (55.4%)/512 (44.6%) <0.001
Tumor differentiation, I–II/III–IV 232 (59.9%)/155 (40.1%) 866 (76.5%)/266 (23.5%) <0.001
BCLC stage, 0/A/B 24 (6.2%)/312 (80.2%)/53 (13.6%) 170 (14.8%)/880 (76.5%)/101 (8.8%) <0.001*
*, Ptrend. Abbreviations: ALT alanine aminotransferase, AST aspartate aminotransferase, γ-GT γ-glutamyl transpeptidase
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(Fig. 1a, e) were associated with both poor OS and poor
RFS. Liver cirrhosis was also associated with poor OS.
The features except BCLC stage that showed an associ-
ation with OS or RFS were adopted for multivariate ana-
lysis. MVI was an independent risk factor for both OS
(HR = 1.425, 95% CI: 1.187–1.712, P < 0.001) and RFS
(HR = 1.404, 95% CI: 1.182–1.667, P < 0.001) (Table 3).
The prognostic value of MVI in subgroups
To study the prognostic value of MVI in patients at a
specific tumor stage, we stratified patients with the
BCLC staging system. Univariate analysis showed that
the presence of MVI was associated with both OS and
RFS in patients with early stage HCC (BCLC stage A;
Fig. 1). In patients with very early stage (BCLC stage 0),
MVI was associated OS but not RFS (Fig. 1c and d, Add-
itional file 1: Table S1; P = 0.028 and P = 0.894). In pa-
tients with intermediate stage HCC (BCLC stage B),
MVI was also associated with RFS but not OS (Fig. 1h
and g, P = 0.039 and P = 0.541).
We then evaluated whether MVI remained an inde-
pendent prognostic factor in BCLC stage A by multivari-
ate analysis (Table 4). MVI remained an independent
risk factor for OS (HR = 1.431, 95% CI, 1.163–1.761, P <
0.001) and RFS (HR = 1.400, 95% CI, 1.150–1.705, P =
0.001) in stage A patients. In stage B patients, MVI was
also an independent risk factor for RFS (Additional file
2: Table S2; HR = 1.562, 95% CI, 1.015–2.405, P = 0.043).
The prognostic significance of MVI was further evalu-
ated in the validation cohort (Additional file 3: Table S3
and Additional file 4: Table S4). In accordance with the
findings in the discovery cohort, MVI was an inde-
pendent risk factor for both OS and RFS in all the
patients (P < 0.001 for both). When patients were
stratified by BCLC stage, MVI was a risk factor for
both OS and RFS for the paints within BCLC A stage
(P = 0.002 and P = 0.003, respectively). In the patients
within BCLC B stage, MVI was also an independent
risk factor for RFS (P < 0.001). In univariate analysis,
although MVI showed associations with poor OS in
patients within BCLC B stage (Additional file 3: Table
S3), and with poor RFS in patients within BCLC 0
stage (Additional file 4: Table S4) it was not an inde-
pendent risk factor in multivariate analysis.
Discussion
In the present study we analyzed the presence and prog-
nostic significance of MVI in patients with HCC who
underwent curative resection. We found that MVI was
an independent risk factor for both OS and RFS. When
patients were stratified by BCLC stages, however, MVI
was an independent risk factor for OS and RFS in pa-
tients at stage A and for RFS in patients at stage B. The
results were similar in two independent cohorts.
MVI is a histological feature of HCC related to aggres-
sive behavior of tumor and is widely accepted as one of
the most important prognostic factors for patients who
undergo curative liver resection or liver transplant. MVI
is an early sign of the spread of tumor cells via the peri-
tumoral blood vessels, which was deemed to be a key
mechanism of intrahepatic tumor dissemination. In the
present study, we found that the presence of MVI in
Table 3 Univariate and multivariate analyses of factors associated with survival and recurrence in the discovery cohort






HR 95% CI P HR 95% CI P
Age, ≤52 vs. >52 year 0.366 NA 0.457 NA
Gender, female vs. male 0.184 NA 0.958 NA
Hepatitis B history, yes vs. no 0.079 NA 0.124 NA
Liver cirrhosis, yes vs. no 0.010 1.493 1.152–1.937 0.002 0.057 NA
α-Fetoprotein, >200 vs. ≤200 ng/dL <0.001 1.559 1.313–1.851 <0.001 <0.001 1.436 1.227–1.681 <0.001
ALT, >75 vs. ≤75 U/L 0.841 NA 0.313 NA
γ-GT, >50 vs. ≤50 U/L <0.001 1.420 1.176–1.715 0.002 <0.001 1.331 1.125–1.575 0.001
Albumin, >35 vs. ≤35 g/L <0.001 0.645 0.501–0.832 0.001 0.003 0.724 0.567–0.926 0.010
Tumor size, >5 vs. ≤5 cm <0.001 2.052 1.715–2.455 <0.001 <0.001 1.724 1.464–2.029 <0.001
Tumor number, solitary vs. multiple <0.001 0.683 0.544–0.857 0.001 <0.001 0.666 0.540–0.822 <0.001
Tumor differentiation, III–IV vs. I–II <0.001 1.275 1.065–1.528 0.008 <0.001 1.290 1.091–1.525 0.003
Tumor encapsulation, complete vs. none <0.001 1.312 1.107–1.554 0.002 <0.001 1.257 1.076–1.468 0.004
Microvascular invasion, yes vs. no <0.001 1.425 1.187–1.712 <0.001 <0.001 1.404 1.182–1.667 <0.001
BCLC stage, 0 vs. A vs. B <0.001 NA <0.001 NA
Abbreviations: ALT alanine aminotransferase, AST aspartate aminotransferase, γ-GT γ-glutamyl transpeptidase, NA not adopted, NS not significant
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Fig. 1 (See legend on next page.)
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HCC patients increased with tumor progression. Pa-
tients with large tumor size, multiple nodules, poor
tumor differentiation, or advanced BCLC stages had a
higher incidence of MVI (Table 2).
Although MVI is an important risk factor in predicting
patient survival after surgery, the present study demon-
strated that MVI may only affect the long-term progno-
sis of patients at specific tumor stages. In HCC patients
at BCLC stage 0 (single tumor ≤ 2 cm), MVI was not as-
sociated with OS or RFS, a finding that is in accord with
previous studies [11, 25, 26]. In patients with very early
stage HCC, anatomical resection was more likely to
completely remove the tumor-bearing portal territory
[27]; therefore, the micro-metastatic nodules infiltrating
peritumoral vasculature, namely the MVI, was removed
with the tumor nodule. In patients at BCLC stage 0, pa-
tients’ age and low albumin were independent risk fac-
tors for OS, indicating that none-tumor factors may act
as the predominant risk factors that determine the long-
term survival in these patients. In patients within BCLC
stage A, univariate and multivariate analysis showed that
MVI status was associated with both OS and RFS. We
think in patients with stage A, MVI as the important
tumor biological character, affected the tumor recur-
rence and overall survival (Table 3). When formulating
adjuvant therapeutic strategies, we should take into ac-
count patients’ MVI status. In patients within BCLC
stage B, MVI was independently associated with RFS but
not with OS. For these patients, although MVI increased
the risk of tumor recurrence but other factors, e.g., AFP
and γ-GT, may undermine its contribution to the long-
term survival.
The prevalence of MVI in HCC patients ranged from
15 to 57.1% among 20 different studies [4]. This wide
interval is explained not only by geographic variations
and the varied features of tumors but also by the lack of
consensus on the definition of MVI in HCC. This is also
a limitation of this study. The incidence of MVI may
have been underestimated in the era before the guideline
to detect MVI was established by a cohort of Chinese
pathologists [28]. The guideline recommend the detec-
tion of MVI on at least 7 points around the tumor nod-
ule from surgery-resected specimens. In order to
highlight the association between MVI status and patient
prognosis, we chose two cohort of patients in the era
(2006–2008) when anti-tumor therapies, e.g., sorafenib,
were not widely used in the adjuvant settings. This is a
retrospective study in a single center, this is a major
limitation of this study, and further investigations are
needed in multi-centric studies.
Conclusions
MVI was an independent risk factor for both OS and
RFS in HCC patients who underwent curative liver
(See figure on previous page.)
Fig. 1 Cumulative overall survival (OS) and recurrence-free survival (RFS) curves of patients with or without microvessel invasion (MVI). MVI was associated
with shorter OS and shorter RFS in all the patients without BCLC stratification (a and b, P< 0.001 for both) and in patients at BCLC stage A (e and f,
P< 0.001 for both). In patients at BCLC stage 0, MVI was associated with OS but not RFS (c and d, P= 0.028 and P= 0.894); and in patients at BCLC stage B,
MVI was associated with RFS but not OS (h and g, P= 0.039 and P= 0.541)
Table 4 Univariate and multivariate analyses of factors associated with survival and recurrence in BCLC stage A patients (n = 1192)






HR 95% CI P HR 95% CI P
Age, ≤52 vs. >52 year 0.751 NA 0.871 NA
Gender, female vs. male 0.434 NA 0.673 NA
Hepatitis B history, yes vs. no 0.025 NS 0.023 NS
Liver cirrhosis, yes vs. no 0.007 1.564 1.181–2.071 0.002 0.030 1.401 1.093–1.796 0.008
α-Fetoprotein, >200 vs. ≤200 ng/dL <0.001 1.644 1.354–1.996 <0.001 <0.001 1.468 1.227–1.758 <0.001
ALT, >75 vs. ≤75 U/L 0.745 NS 0.494 NA
γ-GT, >50 vs. ≤50 U/L <0.001 1.327 1.074–1.640 0.009 <0.001 1.246 1.030–1.509 0.024
Albumin, >35 vs. ≤35 g/L 0.001 NS 0.009 NS
Tumor size, >5 vs. ≤5 cm <0.001 2.080 1.698–2.548 <0.001 <0.001 1.847 1.533–2.225 <0.001
Tumor number, solitary vs. multiple 0.837 NA 0.505 NA
Tumor differentiation, III–IV vs. I–II <0.001 1.272 1.038–1.559 0.020 <0.001 1.250 1.033–1.514 0.022
Tumor encapsulation, complete vs. none <0.001 1.279 1.056–1.549 0.012 0.001 1.225 1.026–1.463 0.025
Microvascular invasion, yes vs. no <0.001 1.431 1.163–1.761 0.001 <0.001 1.400 1.150–1.705 0.001
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resection. However, in patients within BCLC stage 0 or
stage B, MVI examination could not provide further
prognostic information. Only in those at stage A, MVI
could determine patient prognosis.
Additional files
Additional file 1: Table S1. Univariate and multivariate analyses of
factors associated with overall survival in BCLC stage 0 patients (n = 194)
in the discovery cohort. (DOCX 13 kb)
Additional file 2: Table S2. Univariate and multivariate analyses of
factors associated with recurrence-free survival in BCLC stage B patients
(n = 154) in the discovery cohort. (DOCX 13 kb)
Additional file 3: Table S3. Univariate analyses of factors associated
with overall survival in the patients from the validation cohort or
stratified by BCLC stage. (DOCX 13 kb)
Additional file 4: Table S4. Univariate analyses of factors associated
with recurrence-free survival in the patients from the validation cohort or
stratified by BCLC stage. (DOCX 13 kb)
Abbreviations
AASLD: American Association for the Study of Liver Diseases; AFP: α-
fetoprotein; BCLC: Barcelona Clinic Liver Cancer; EASL: European Association
for the Study of the Liver; HCC: Hepatocellular carcinoma; HR: Hazard ratio;





This study was supported by the National Natural Science Foundation of
China (No. 81572298 and 81372655), “973” State Key Basic Research Program
of China (No. 2015CB554000), the National Key Basic Research Program (973
project) (2015CB554005) from the Ministry of Science and Technology of
China Leading Investigator Program of Shanghai municipal government
(2016). All the funding bodies did not participated in the design of the study
and in data collection, analysis, and interpretation and in writing the
manuscript.
Availability of data and material
All data generated or analyzed during this study are included in this
published article and its supplementary information files.
Authors’ contributions
CH, X-DZ, and H-CS analyzed data, and wrote the manuscript. YJ, G-YD, G-
MS, and Y-HS, collected the data, reviewed and edited the manuscript. JZ
and JF designed the experiments, reviewed and edited the manuscript. All of
the authors have read the manuscript and approved its submission.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
This study was approved by the Zhongshan Hospital Fudan University
Research Ethics Committee. Informed consent was obtained according to
the regulations. Informed consent obtained from the patients was written.
Author details
1Liver Cancer Institute and Zhongshan Hospital, Fudan University, Key
Laboratory for Carcinogenesis and Cancer Invasion, the Chinese Ministry of
Education, 136 Yi Xue Yuan Rd, Shanghai 200032, China. 2Department of
Pathology, Zhongshan Hospital, Fudan University, 136 Yi Xue Yuan Rd,
Shanghai 200032, China.
Received: 30 August 2016 Accepted: 9 January 2017
References
1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM,
Forman D, Bray F. Cancer incidence and mortality worldwide: sources,
methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:
E359–86.
2. Dhir M, Melin AA, Douaiher J, Lin C, Zhen WK, Hussain SM, Geschwind JH,
Doyle MB, Abou-Alfa GK, Are C. A review and update of treatment options
and controversies in the management of hepatocellular carcinoma. Annals
of Surgery. 2016;263:1112–25.
3. Du M, Chen L, Zhao J, Tian F, Zeng H, Tan Y, Sun H, Zhou J, Ji Y.
Microvascular invasion (MVI) is a poorer prognostic predictor for small
hepatocellular carcinoma. BMC Cancer. 2014;14:38.
4. Rodriguez-Peralvarez M, Luong TV, Andreana L, Meyer T, Dhillon AP,
Burroughs AK. A systematic review of microvascular invasion in
hepatocellular carcinoma: diagnostic and prognostic variability. Ann Surg
Oncol. 2013;20:325–39.
5. Huang C, Wang Y, Liu S, Ding G, Liu W, Zhou J, Kuang M, Ji Y, Kondo T, Fan
J. Quantitative proteomic analysis identified paraoxonase 1 as a novel
serum biomarker for microvascular invasion in hepatocellular carcinoma. J
Proteome Res. 2013;12:1838–46.
6. Roayaie S, Blume IN, Thung SN, Guido M, Fiel MI, Hiotis S, Labow DM, Llovet
JM, Schwartz ME. A system of classifying microvascular invasion to predict
outcome after resection in patients with hepatocellular carcinoma.
Gastroenterology. 2009;137:850–5.
7. Ye QH, Qin LX, Forgues M, He P, Kim JW, Peng AC, Simon R, Li Y, Robles AI,
Chen Y, et al. Predicting hepatitis B virus-positive metastatic hepatocellular
carcinomas using gene expression profiling and supervised machine
learning. Nat Med. 2003;9:416–23.
8. Sumie S, Kuromatsu R, Okuda K, Ando E, Takata A, Fukushima N, Watanabe
Y, Kojiro M, Sata M. Microvascular invasion in patients with hepatocellular
carcinoma and its predictable clinicopathological factors. Ann Surg Oncol.
2008;15:1375–82.
9. Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, Camerini T,
Roayaie S, Schwartz ME, Grazi GL, et al. Predicting survival after liver
transplantation in patients with hepatocellular carcinoma beyond the Milan
criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10:35–43.
10. Lee HH, Joh JW, Park JH, Lee KW, Heo JS, Choi SH, Kim SJ, Lee SK.
Microvascular tumor embolism: independent prognostic factor after liver
transplantation in hepatocellular carcinoma. Transplant Proc. 2005;37:1251–3.
11. Shindoh J, Andreou A, Aloia TA, Zimmitti G, Lauwers GY, Laurent A,
Nagorney DM, Belghiti J, Cherqui D, Poon RT, et al. Microvascular invasion
does not predict long-term survival in hepatocellular carcinoma up to 2 cm:
reappraisal of the staging system for solitary tumors. Ann Surg Oncol. 2013;
20:1223–9.
12. Portolani N, Baiocchi GL, Molfino S, Benetti A, Gheza F, Giulini SM.
Microvascular infiltration has limited clinical value for treatment and
prognosis in hepatocellular carcinoma. World J Surg. 2014;38:1769–76.
13. European Association For The Study Of The L, European Organisation For R,
Treatment Of C. EASL-EORTC Clinical Practice Guidelines: management of
hepatocellular carcinoma. J Hepatol. 2012;56:908–43.
14. Bruix J, Sherman M, American Association for the Study of Liver D.
Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:
1020–2.
15. Lee S, Kim BK, Song K, Park JY, Ahn SH, Kim SU, Han KH, Kim do Y, Korea
Central Cancer R. Subclassification of Barcelona Clinic Liver Cancer B and C
hepatocellular carcinoma: a cohort study of the multicenter registry
database. J Gastroenterol Hepatol. 2016;31:842–7.
16. Zhong JH, Ke Y, Gong WF, Xiang BD, Ma L, Ye XP, Peng T, Xie GS, Li LQ.
Hepatic resection associated with good survival for selected patients with
intermediate and advanced-stage hepatocellular carcinoma. Ann Surg. 2014;
260:329–40.
17. Liu W, Zhou JG, Sun Y, Zhang L, Xing BC. Hepatic resection improved the
long-term survival of patients with BCLC stage B hepatocellular carcinoma
in Asia: a systematic review and meta-analysis. J Gastrointest Surg. 2015;19:
1271–80.
18. Ciria R, Lopez-Cillero P, Gallardo AB, Cabrera J, Pleguezuelo M, Ayllon MD,
Luque A, Zurera L, Espejo JJ, Rodriguez-Peralvarez M, et al. Optimizing the
management of patients with BCLC stage-B hepatocellular carcinoma:
Huang et al. BMC Cancer  (2017) 17:58 Page 7 of 8
modern surgical resection as a feasible alternative to transarterial
chemoemolization. Eur J Surg Oncol. 2015;41:1153–61.
19. Park JW, Chen M, Colombo M, Roberts LR, Schwartz M, Chen PJ, Kudo M,
Johnson P, Wagner S, Orsini LS, et al. Global patterns of hepatocellular
carcinoma management from diagnosis to death: the BRIDGE Study. Liver
Int. 2015;35:2155–66.
20. Torzilli G, Belghiti J, Kokudo N, Takayama T, Capussotti L, Nuzzo G, Vauthey
JN, Choti MA, De Santibanes E, Donadon M, et al. A snapshot of the
effective indications and results of surgery for hepatocellular carcinoma in
tertiary referral centers: is it adherent to the EASL/AASLD
recommendations?: An observational study of the HCC East–west study
group. Ann Surg. 2013;257:929–37.
21. Chok KS, Cheung TT, Chan SC, Poon RT, Fan ST, Lo CM. Surgical outcomes
in hepatocellular carcinoma patients with portal vein tumor thrombosis.
World J Surg. 2014;38:490–6.
22. Poon RT, Cheung TT, Kwok PC, Lee AS, Li TW, Loke KL, Chan SL, Cheung
MT, Lai TW, Cheung CC, et al. Hong Kong consensus recommendations on
the management of hepatocellular carcinoma. Liver Cancer. 2015;4:51–69.
23. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC
staging classification. Semin Liver Dis. 1999;19:329–38.
24. Sun HC, Zhang W, Qin LX, Zhang BH, Ye QH, Wang L, Ren N, Zhuang PY, Zhu
XD, Fan J, et al. Positive serum hepatitis B e antigen is associated with higher
risk of early recurrence and poorer survival in patients after curative resection
of hepatitis B-related hepatocellular carcinoma. J Hepatol. 2007;47:684–90.
25. Yamashita Y, Tsuijita E, Takeishi K, Fujiwara M, Kira S, Mori M, Aishima S,
Taketomi A, Shirabe K, Ishida T, et al. Predictors for microinvasion of small
hepatocellular carcinoma </= 2 cm. Ann Surg Oncol. 2012;19:2027–34.
26. Roayaie S, Obeidat K, Sposito C, Mariani L, Bhoori S, Pellegrinelli A, Labow D,
Llovet JM, Schwartz M, Mazzaferro V. Resection of hepatocellular cancer
</=2 cm: results from two Western centers. Hepatology. 2013;57:1426–35.
27. Shindoh J, Makuuchi M, Matsuyama Y, Mise Y, Arita J, Sakamoto Y, Hasegawa
K, Kokudo N. Complete removal of the tumor-bearing portal territory
decreases local tumor recurrence and improves disease-specific survival of
patients with hepatocellular carcinoma. J Hepatol. 2016;64:594–600.
28. Cancer CSoL, Group CA-CALCs, Hepatology CSo, Pathology CMACSo, Group
CA-CADD, Pathology CSo, Group CMALS, Surgery CSo, Oncology CMACSoC,
Transplantation CA-CACPGoHTaL. Evidence-based practice guidelines for
the standardized pathological diagnosis of primary liver cancer (2015
edition) (in Chinese). Chin J Hepatobiliary Surg. 2015;21:145–51.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Huang et al. BMC Cancer  (2017) 17:58 Page 8 of 8
